Aurora Cannabis (ACB) Stock Price, News & Analysis

Company Overview

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.

Key Stats

• Today's Range: C$4.21 to C$4.39
• 50-Day Range: C$4.25 to C$5.23
• 52-Week Range: C$3.77 to C$9.33
• Volume: 490,718 shs
• Average Volume: 413,289 shs
• Market Capitalization: C$251.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$7.67
• Consensus Rating: Buy

Aurora Cannabis Stock Analysis - MarketRank™

Aurora Cannabis scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Aurora Cannabis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Aurora Cannabis has a consensus price target of C$7.67, representing about 80.4% upside from its current price of C$4.25.

Amount of Analyst Coverage

Aurora Cannabis has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aurora Cannabis is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aurora Cannabis is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aurora Cannabis has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ACB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aurora Cannabis does not currently pay a dividend.

Dividend Growth

Aurora Cannabis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.03

News Sentiment

Aurora Cannabis has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Aurora Cannabis this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for ACB on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.

MarketBeat Follows

1 people have added Aurora Cannabis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aurora Cannabis insiders have not sold or bought any company stock.

Percentage Held by Institutions

4.56% of the stock of Aurora Cannabis is held by institutions.

Company Calendar

• Last Earnings: 6/11/2026
• Today: 6/13/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:ACB
• CIK: N/A
• Web: auroramj.com
• Phone: +1-604-3625207
• Fax: N/A
• Employees: 1,073
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aurora Cannabis: C$7.67
• High Price Target: C$8.50
• Low Price Target: C$6.50
• Potential Upside/Downside: +80.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): C($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$44.16 million
• Net Margins: -12.13%
• Pretax Margin: N/A
• Return on Equity: -7.25%
• Return on Assets: -1.87%

Debt

• Debt-to-Equity Ratio: 4.66
• Current Ratio: 5.94
• Quick Ratio: 2.48

Sales & Book Value

• Annual Sales: C$373.12 million
• Price / Sales: 0.67
• Cash Flow: C$3.41 per share
• Price / Cash Flow: 1.25
• Book Value: C$8.91 per share
• Price / Book: 0.48

Miscellaneous

• Outstanding Shares: 59,127,000
• Free Float: N/A
• Market Cap: C$251.29 million
• Optionable: Not Optionable
• Beta: 0.17